President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
Groups protest insulin prices outside Lilly headquarters
Several diabetes and health care advocacy groups on Thursday announced a seven-figure fundraising campaign to help fund their fight against what they consider “skyrocketing” insulin prices.Read More
The Trump administration said Wednesday it will create a pathway allowing Americans to legally and safely import lower-cost prescription drugs from Canada for the first time, reversing years of opposition from federal health authorities.
The new publicly traded company will have sales of about $19 billion to $20 billion in 2020, the drugmakers said in a statement.
The meeting occurred as a bipartisan effort is underway in the Senate that two of its sponsors say would lead to $100 billion in savings on prescription-drug spending over a decade.
Iowa Republican Charles Grassley and Oregon Democrat Ron Wyden said the bill would for the first time limit drug copays for people with Medicare’s “Part D” prescription plan, by capping patients’ out-of-pocket costs.
Records kept by the federal Drug Enforcement Administration show that 76 billion oxycodone and hydrocodone pills—the vast majority of them generics, not brand names—were shipped to U.S. pharmacies from 2006 to 2012.
U.S. overdose deaths last year likely fell for the first time in nearly three decades, preliminary statistics suggest.
The trial in Oklahoma City is the first of more than 1,900 local U.S. government lawsuits against drug makers and distributors over the fallout from opioid abuse.
The multibillion-dollar merger would combine Elanco, the fourth-largest global player in animal health, with Bayer’s pet-health division, which ranks fifth in veterinary medicine, Reuters reported. The combination would create a dominant force in the industry.
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.
In recent months, the drugmaker has won federal approval to sell a drug called Emgality for two conditions: migraine pain and cluster headaches.
The American Medical Association Opioid Task Force 2019 Progress Report shows Indiana's reduction in opioid prescriptions from 2013 to 2018 is two percentage points higher than the national average.
Some of the biggest pharmaceutical companies, including Indianapolis-based Eli Lilly and Co., sued the Trump administration to try and block a rule that would force them to put the price of their drugs in television advertisements.
“Our central focus as a company is always to make lives better. … It’s a value that is core to every single employee who works here. So if we can have programs that reinforce that we are a company that is focused on making lives better, then we are doing something that connects to our mission and reminds our employees what really matters to us as a company.”
The fast-acting insulin, which diabetics inject shortly before each meal, is used by about 700,000 Americans.
The Indiana lawsuit was filed Monday against eight members of Sackler family who own Connecticut-based drugmaker Purdue Pharma.
The Trump administration has finalized regulations that will require drug companies to disclose list prices of medications costing more than $35 for a month’s supply.
A pharmaceutical company founder accused of paying doctors millions in bribes to prescribe a highly addictive fentanyl spray was convicted Thursday in a case that exposed such marketing tactics as using a stripper-turned-sales-rep to give a physician a lap dance.
Caprice R. Bearden, the company’s former compliance officer, pleaded guilty in November to multiple criminal charges related to the sale of over-potent drugs. She later testified against her boss, who was convicted and awaits sentencing.
Indianapolis-based Eli Lilly and Co. was one of the first drug firms to begin sharing prices. Now, others are following suit.